Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income	$ 77,266	$ 66,472	$ 49,114
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,359	25,654	24,499
Non-cash stock-based expense	10,034	5,621	3,251
Acceleration of interest expense related to debt conversion	0	0	5,205
(Gain) loss on sale of assets	(42)	77	(540)
Deferred income taxes	12,571	(13,195)	22,026
Distributions from long-term investments	1,347	1,258	1,416
Gain on liquidation of long-term investments accounted for at cost	(189)	0	0
Equity in losses (earnings) from long-term investments	2,754	2,681	(3,140)
(Gain) loss on sale of investment securities available for sale	(2,907)	(11,138)	11
Equity in earnings from real estate ventures	(5,200)	(2,001)	(4,103)
Distributions from real estate ventures	23,446	5,894	5,152
Non-cash interest expense	(10,549)	(6,504)	(35,584)
Impairment of investment securities	5,381	12,846	0
Impairment of long-term investments	1,587	811	0
Impairment of real estate, net	0	230	0
Changes in assets and liabilities:
Receivables	(5,809)	(1,414)	(11,197)
Inventories	(3,317)	3,806	3,173
Accounts payable and accrued liabilities	(22,922)	37,936	5,708
Payments due under the Master Settlement Agreement	(10,968)	(2,796)	(925)
Other assets and liabilities, net	(18,304)	5,233	(27,858)
Net cash provided by operating activities	97,636	144,479	107,376
Cash flows from investing activities:
Sale of investment securities	116,070	270,576	154,615
Maturities of investment securities	10,822	5,491	930
Purchase of investment securities	(117,211)	(214,146)	(305,731)
Proceeds from sale or liquidation of long-term investments	4,552	1,303	2,416
Purchase of long-term investments	(50)	(10,000)	(12,000)
Decrease (increase) in restricted assets	10,181	(6,889)	(872)
Investments in real estate ventures	(44,107)	(70,272)	(40,916)
Distributions from real estate ventures	33,204	17,563	7,309
Issuance of notes receivable	0	(4,410)	(8,250)
Proceeds from sale of fixed assets	45	4	4
Capital expenditures	(26,691)	(10,977)	(23,404)
Increase in cash surrender value of life insurance policies	(484)	(1,742)	(484)
Purchase of subsidiaries	(250)	0	(750)
Repayment of notes receivable	4,410	4,000	4,850
Purchase of preferred securities	0	0	(1,000)
Pay down of investment securities	9,212	8,739	1,849
Proceeds from sale of preferred securities	0	1,000	0
Investments in real estate held for sale	(245)	(12,603)	0
Net cash used in investing activities	(542)	(22,363)	(221,434)
Cash flows from financing activities:
Proceeds from issuance of debt	243,620	2,105	413,914
Repayments of debt	(5,365)	(6,684)	(12,601)
Deferred financing costs	(6,600)	(624)	(12,360)
Borrowings under revolver	144,294	153,361	886,130
Repayments on revolver	(110,614)	(167,915)	(898,788)
Dividends and distributions on common stock	(198,947)	(188,151)	(167,328)
Distributions to non-controlling interest	(11,545)	(3,280)	(9,339)
Contributions from non-controlling interest	248	813	0
Proceeds from exercise of Vector options	398	1,441	5,151
Tax benefit of options exercised	579	821	1,178
Net cash provided by (used in) financing activities	56,068	(208,113)	205,957
Net increase (decrease) in cash and cash equivalents	153,162	(85,997)	91,899
Cash and cash equivalents, beginning of year	240,368	326,365	234,466
Cash and cash equivalents, end of year	$ 393,530	$ 240,368	$ 326,365